INTRODUCTION
malignancies, GBM, Glioblastoma, colorectal and gastric cancers
MALIGNANCIES, GLIOBLASTOMA
Glioblastoma (GBM) is one of the most devastating malignancies with a median survival of 15 months.Many studies explored the genomic landscape of GBMs; alterations of the epidermal growth factor receptor (Numerous anti‐EGFR agents have been evaluated in GBMs.Regarding this GBM‐specific characteristic, an anti‐EGFR antibody can be an ideal option for GBMs. While previous studies with anti‐EGFR antibodies were disappointing,GC1118, a novel anti‐EGFR antibody, may have selective advantages to GBMs over other anti‐EGFR antibodies; first, GC1118 has a distinct binding epitope. It recognizes a unique and critical EGFR epitope for EGF binding which does not overlap with those of other anti‐EGFR antibodies.GC1118 has already demonstrated potential antitumor efficacy in colorectal and gastric cancers.In this study, we aimed to evaluate the antitumor effect of GC1118 against GBM patients with 